| [1] Yap M S, Tang Y Q, Yeo Y, et al.Pluripotent human embryonic stem cell derived neural lineages for in vitro modelling of enterovirus 71 infection and therapy. Virol J,2016,13(1):5.
[2] Peng Y. The patentability of human embryonic stem cell technology in China. Nat Biotechnol, 2016,34(1):37-39.
[3] Plaza Reyes A, Petrus-Reurer S, Antonsson L, et al. Xeno-free and defined human embryonic stem cell-derived retinal pigment epithelial cells functionally integrate in a large-eyed preclinical model. Stem Cell Reports, 2016,6(1):9-17.
[4] Espinoza N, Peterson M. How to depolarise the ethical debate over human embryonic stem cell research (and other ethical debates too!). J Med Ethics,2012,38(8):496-500.
[5] Ehrich K, Williams C, Farsides B. Consenting futures:professional views on social, clinical and ethical aspects of information feedback to embryo donors in human embryonic stem cell research. Clin Ethics,2010,5(2):77-85.
[6] Haimes E, Taylor K. The contributions of empirical evidence to socio-ethical debates on fresh embryo donation for human embryonic stem cell research. Bioethics,2011,25(6):334-341.
[7] 康亚妮,刘皓. 人类胚胎干细胞来源引发的伦理问题. 中国医学伦理学,2004,17(93):15-16. Kang Y N, Liu H. Ethical issues of human embryonic stem cell sources. Chinese Journal of Medical Ethics, 2004,17(93):15-16.
[8] Cohen C B. Ethical and policy issues surrounding the donation of cryopreserved and fresh embryos for human embryonic stem cell research. Stem Cell Rev,2009,5(2):116-122.
[9] 王佃亮. 移植细胞的种类及其有效性和安全性. 中国生物工程杂志,2013,33(9):119-125. Wang D L. The types,safety and efficacity of the transplanted cells. China Biotechnology, 2013, 33(9):119-125.
[10] Si Y, Yang K, Qin M, et al. Efficacy and safety of human umbilical cord derived mesenchymal stem cell therapy in children with severe aplastic anemia following allogeneic hematopoietic stem cell transplantation:a retrospective case series of 37 patients.Pediatr Hematol Oncol,2014,31(1):39-49.
[11] Zhang Z, Fu J, Xu X, et al. Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients.AIDS,2013,27(8):1283-1293.
[12] Gruen L, Grabel L. Concise review:scientific and ethical roadblocks to human embryonic stem cell therapy.Stem Cells,2006,24(10):2162-2169.
[13] Reinders M E, Dreyer G J, Bank J R, et al. Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients:the neptune study. J Transl Med,2015,13:344.
[14] Bole-Richard E, Deschamps M, Ferrand C, et al. Editorial:improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol,2015,6:174.
[15] Williams J K, Eckman D, Dean A, et al. The dose-effect safety profile of skeletal muscle precursor cell therapy in a dog model of intrinsic urinary sphincter deficiency.Stem Cells Transl Med,2015,4(3):286-294.
[16] Pawitan J A.Prospect of cell therapy for Parkinson's disease.Anat Cell Biol, 2011,44(4):256-264.
[17] Hashmi S, Ahmed M, Murad M H, et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease:systematic review and meta-analysis. Lancet Haematol,2016,3(1):45-52.
[18] Shetty A K, Upadhya D. GABA-ergic cell therapy for epilepsy:Advances, limitations and challenges.Neurosci Biobehav Rev,2015,62:35-47.
[19] Gross G, Eshhar Z. Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment:counteracting off-tumor toxicities for safe CAR T cell therapy. Annu Rev Pharmacol Toxicol,2016,56:59-83.
[20] Schimke M M, Marozin S, Lepperdinger G. Patient-specific age:the other side of the coin in advanced mesenchymal stem cell therapy. Front Physiol, 2015,6:362.
[21] Golpanian S, Schulman I H, Ebert R F, et al. Concise review:review and perspective of cell dosage and routes of administration from preclinical and clinical studies of stem cell therapy for heart disease.Stem Cells Transl Med,2016,5(2):186-191. |
